Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHFS

Nuwellis (CHFS) Stock Price, News & Analysis

Nuwellis logo

About Nuwellis Stock (NASDAQ:CHFS)

Advanced Chart

Key Stats

Today's Range
$4.01
$4.35
50-Day Range
$3.53
$6.02
52-Week Range
$4.86
$37.50
Volume
74,779 shs
Average Volume
467,323 shs
Market Capitalization
$25.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CHFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHFS Stock News Headlines

Nuwellis Secures NIH Grant for Pediatric Device Development
Nuwellis Gains FDA Clearance for New Catheter
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Nuwellis Appoints John L. Erb as CEO
See More Headlines

CHFS Stock Analysis - Frequently Asked Questions

Nuwellis, Inc. (NASDAQ:CHFS) released its earnings results on Monday, March, 1st. The company reported ($1.57) EPS for the quarter, beating the consensus estimate of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.

Nuwellis shares reverse split on Friday, October 13th 2017.The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Prima BioMed (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/01/2021
Today
9/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:CHFS
Previous Symbol
NASDAQ:SSH
CIK
1506492
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($279.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.11 million
Net Margins
-254.26%
Pretax Margin
N/A
Return on Equity
-173.61%
Return on Assets
-131.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.87
Quick Ratio
5.97

Sales & Book Value

Annual Sales
$5.51 million
Price / Sales
4.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.79 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
6,037,000
Free Float
N/A
Market Cap
$25.42 million
Optionable
Not Optionable
Beta
1.55
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CHFS) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners